**Supplemental Table S2. 21st to 50th most frequent MeSH terms located in all the levels beneath the MeSH term “Eye Diseases” in the MeSH tree and co-occurrence of MeSH terms in articles**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| MeSH terms located beneath "Eye Diseases" | Number of articles indexed with this MeSH term (%) | Five most co-occurring MeSH terms in articles with the MeSH term in the first column (% of co-occurrence) |  | MeSH terms located beneath "Eye Diseases" (continued) | Number of articles indexed with this MeSH term (%) | Five most co-occurring MeSH terms in articles with the MeSH term in the first column (% of co-occurrence) |
| Ocular Hypertension (L1) | 1005 (1.62) | Intraocular Pressure (74.13)Tonometry, Ocular (32.64)Glaucoma, Open-Angle (31.94)Glaucoma (28.36)Antihypertensive Agents (24.18) |  | Eye Neoplasms (L1) | 687 (1.11) | Retrospective Studies (17.47)Melanoma (16.01)Treatment Outcome (15.87)Lacrimal Apparatus Diseases (13.10)Diagnosis Differential (11.35) |
| Keratoconus (L2) | 1001 (1.61) | Visual Acuity (44.46)Corneal Topography (41.06)Cornea (33.37)Corneal Stroma (30.67)Collagen (23.88) |  | Vision, Low (L2) | 677 (1.09) | Visual Acuity (41.51)Blindness (30.13)Visually Impaired Persons (24.96)Prevalence (18.02)Questionnaires (16.54) |
| Graves Disease (L3) | 999 (1.61) | Antithyroid Agents (19.42)Thyroid Gland (18.72)Treatment Outcome (14.11)Thyroidectomy (12.71)Hashimoto Disease (12.61) |  | Retinal Vein Occlusion (L2) | 676 (1.09) | Visual Acuity (47.93)Macular edema (47.34)Tomography, Optical Coherence (32.54)Intravitreal Injections (28.99)Antibodies Monoclonal Humanized (28.11) |
| Astigmatism (L2) | 947 (1.52) | Visual Acuity (59.03)Refraction Ocular (42.03)Myopia (32.73)Treatment Outcome (29.36)Corneal Topography(28.41) |  | Eye Abnormalities (L1) | 671 (1.08) | Mutation (17.88)Retina (17.44)Abnormalities Multiple (15.95)Cerebellar Diseases (14.31)Kidney Diseases Cystic (13.86) |
| Refractive Errors (L1) | 943 (1.52) | Visual Acuity (41.99)Refraction Ocular (28.95)Retrospective Studies (17.60)Prevalence (16.33)Cross-Sectional\_Studies (13.36) |  | Retinal Perforations (L2) | 648 (1.04) | Vitrectomy (57.41)Visual Acuity (56.33)Tomography, Optical Coherence (51.23)Retrospective Studies (39.04)Retinal Detachment (29.32) |
| Retinitis Pigmentosa (L2)  | 899 (1.45) | Mutation (28.70)Electroretinography (22.47)Retina (22.36)Pedigree (21.91)Eye Proteins (19.02) |  | Orbital Diseases (L1) | 647 (1.04) | Tomography, X-Ray Computed (32.61)Magnetic Resonance Imaging (20.71)Retrospective Studies (17.00)Diagnosis Differential (16.23)Orbit (13.60) |
| Eye Injuries (L1) | 867 (1.40) | Visual Acuity (21.34)Retrospective Studies (17.30)Wounds Nonpenetrating (17.30)Corneal Injuries (10.5)Treatment Outcome (10.15) |  | Retinal Neoplasms (L2)  | 634 (1.02) | Retinoblastoma (79.02)Retrospective Studies (22.08)Eye Enucleation (17.51)Treatment Outcome (17.03)Follow-Up Studies (13.56) |
| Orbital Neoplasms (L2) | 850 (1.37) | Magnetic Resonance Imaging (28.47)Tomography, X-Ray Computed (27.76)Retrospective studies (18.12)Treatment Outcome (17.06)Diagnosis Differential (16.82) |  | Diplopia (L2) | 627 (1.01) | Magnetic Resonance Imaging (25.84)Tomography, X-Ray Computed (23.76)Retrospective Studies (20.89)Treatment Outcome (19.94)Oculomotor Muscles (19.62) |
| Retinopathy of Prematurity (L2) | 825 (1.33) | Gestational Age (35.03)Retrospective Studies (19.76)Risk Factors (19.52)Oxygen (16)Birth Weight (15.39) |  | Uveal Neoplasms (L2) | 621 (1) | Melanoma (90.18)Retrospective Studies (18.52)Prognosis (16.75)Eye Enucleation (14.81)Treatment Outcome (14.01) |
| Strabismus (L2) | 807 (1.3) | Oculomotor Muscles (35.69)Ophthalmologic Surgical Procedures (25.4)Visual Acuity (25.15)Vision Binocular (21.93)Retrospective\_Studies (20.32) |  | Ocular Motility Disorders (L1) | 593 (0.95) | Magnetic Resonance Imaging (18.72)Eye Movements (16.19)Oculomotor Muscles (14.67)Retrospective Studies (12.98)Visual Acuity (11.97) |
| Neuromyelitis Optica (L3) | 766 (1.23) | Aquaporin 4 (45.30)Autoantibodies (32.25)Multiple Sclerosis (28.59)Magnetic Resonance Imaging (25.98)Immunoglobulin G (18.28) |  | Amblyopia (L2) | 585 (0.94) | Visual Acuity (48.89)Strabismus (26.50)Vision Binocular (17.26)Treatment Outcome (16.75)Retrospective Studies (16.24) |
| Eye Infections, Bacterial (L2) | 741 (1.19) | Anti-Bacterial Agents (44.80)Endophthalmitis (29.01)Retrospective Studies (28.21)Visual Acuity (23.48)Corneal Ulcer (23.08) |  | Glaucoma, Angle-Closure (L3) | 580 (0.93) | Intraocular Pressure (51.90)Gonioscopy (29.31)Tomography, Optical Coherence (26.21)Glaucoma Open-Angle (23.28)Tonometry Ocular (22.24) |
| Eyelid Diseases (L1) | 737 (1.19) | Eyelids (20.76)Treatment Outcome (17.91)Retrospective Studies(17.77)Meibomian Glands (14.25)Blepharoplasty (11.80)) |  | Retinal Neovascularization (L2) | 568 (0.91) | Vascular Endothelial Growth Factor A (37.85)Disease Models Animal (32.75)Mice Inbred C57BL (27.82)Angiogenesis Inhibitors (26.41)Fluorescein Angiography (26.23) |
| Keratitis (L2) | 707 (1.14) | Cornea (23.06)Eye Infections, Fungal (15.13)Eye Infections, Bacterial (13.30)Retrospective Studies (12.59)Antifungal Agents (11.03) |  | Blepharoptosis (L2) | 567 (0.91) | Oculomotor Muscles (23.63) ;Blepharoplasty (21.87) ;Treatment Outcome (21.52);Eyelids (21.34);Retrospective Studies (18.52) |
| Endophthalmitis (L2) | 692 (1.11) | Anti-Bacterial Agents (35.26)Eye Infections Bacterial (31.07)Retrospective Studies (25)Visual Acuity (23.12)Postoperative Complications (22.98) |  | Wet Macular Degeneration (L4) | 553 (0.89) | Angiogenesis Inhibitors (58.41) ;Visual Acuity (57.50) ;Antibodies Monoclonal Humanized (52.80);Tomography, Optical Coherence (47.02);Vascular Endothelial Growth Factor A (46.11) |

(L1), (L2), (L3), (L4), (L5): Levels in the MeSH tree beneath the MeSH term “Eye Diseases”, respectively first, second, third, fourth, and fifth levels